Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients with AIDS

Rachlis, Anita; Smaill, Fiona; Walker, Valery; Hotchkies, Lorraine; Jones, A J

doi:10.2165/00019053-199916010-00007

Cited by 5 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, Rachfrom early detection and treatment with triple ART. These re-lis [234] compared intravenous ganciclovir with oral ganciclovir for searchers estimated that the cost effectiveness of this early diagno-the treatment of cytomegalovirus (CMV), obtaining a cost-effecsis was approximately £50 000 ($US91 592) per maternal LYG, tiveness ratio of $US482 per progression-free day, which correand concluded that this was too high to promote testing of mothers.…”

Section: Other Art-related Issuesmentioning

confidence: 99%

“…[145,[147][148][149][150][151]153,157,[159][160][161]163,164,174] While more than half tried to ble to know which drugs were being used, other than the specific adjust for differences in geographic settings, prophylaxis regimen intervention to treat the OI under observalengths or other factors, these studies often had to make consideration. [230,231,233,234,240,241,243,254] This information is important, since a ble assumptions to fit the data to these differing contexts.…”

Section: Cytomegalovirus Prophylaxismentioning

confidence: 99%

See 1 more Smart Citation

Efficiency of Interventions in HIV Infection, 1994???2004

Harling

Wood

Beck

2005

Disease Management & Health Outcomes

View full text Add to dashboard Cite

Section: Other Art-related Issuesmentioning

confidence: 99%

Section: Cytomegalovirus Prophylaxismentioning

confidence: 99%

Efficiency of Interventions in HIV Infection, 1994???2004

Harling

Wood

Beck

2005

Disease Management & Health Outcomes

View full text Add to dashboard Cite

“…Disease progression was a main outcome measure. 119 Cost-benefit analysis involves the comparison of a range of outcomes or benefits of a programme. The researcher has to make a decision regarding which outcomes are to be included and to whom (eg, direct and indirect costs to health services, patients, their families or other carers).…”

Section: Costsmentioning

confidence: 99%

HEALTH SERVICES RESEARCH METHODS IN PHARMACY: Evaluation of pharmaceutical services: (2) Methods and measures

Smith

2000

International Journal of Pharmacy Practice

View full text Add to dashboard Cite

Numerous studies have been undertaken to evaluate pharmaceutical services. These include both the evaluation of existing practice and assessments of innovative services in both hospital and community settings. Evaluation requires employment of methods and measures to ensure that relevant data on the effects of a programme are obtained. To evaluate a service from different perspectives (eg, acceptability to health professionals or patients, uptake, clinical outcomes or resource implications), a number of methods may be required. The outcomes may also be wide‐ranging. Measures must be selected which provide a true reflection of the extent to which these outcomes are, or are not, achieved. Designs and frameworks used in the evaluation of pharmacy services have been discussed previously,1 this paper reviews the methods and measures that have been employed.

show abstract

The Epidemiology, Treatment Patterns, and Costs of Cytomegalovirus Retinitis in the Post-HAART Era Among a National Managed-Care Population

Mahadevia¹,

Gebo²,

Pettit³

et al. 2004

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

To examine the epidemiology, treatment patterns, and costs of cytomegalovirus (CMV) retinitis treatment in the post-HAART (highly active antiretroviral therapy) era, a retrospective cohort study was performed using data from US managed-care plans from 1997-2002. Cases with CMV retinitis were defined by requiring diagnosis codes for HIV (or AIDS), CMV, and retinitis and claims for anti-CMV treatment. Costs of oral, intravenous, and intraocular treatment periods were examined. The incidence of enrolled HIV or AIDS cases increased from 7 per million members in 1997 to 150 per million members in 2001. The incidence of CMV retinitis decreased from 23 per 10,000 HIV or AIDS cases in 1997 to 8 per 10,000 HIV or AIDS cases in 2001. The average duration of a CMV episode was 192 days and the average cost was 19,576 US dollars. In a multiple linear regression model adjusting for age, gender, insurance type, geographic region, HAART use, and co-existing AIDS-defining illnesses, intraocular and oral treatment periods saved 7135 and US dollars and 6866 US dollars, respectively, per treatment period compared with intravenous treatment (P < 0.05). The incidence of CMV retinitis decreased in this managed-care population during the post-HAART era. Use of oral or intraocular treatment saves costs compared with intravenous treatment in a managed-care environment.

show abstract

Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients with AIDS

Abstract: This analysis found that i.v. ganciclovir provided additional days free of progression of CMV retinitis when compared with oral ganciclovir, but the costs were higher.

Cited by 5 publications

References 5 publications

Efficiency of Interventions in HIV Infection, 1994???2004

Efficiency of Interventions in HIV Infection, 1994???2004

HEALTH SERVICES RESEARCH METHODS IN PHARMACY: Evaluation of pharmaceutical services: (2) Methods and measures

The Epidemiology, Treatment Patterns, and Costs of Cytomegalovirus Retinitis in the Post-HAART Era Among a National Managed-Care Population

Contact Info

Product

Resources

About